Company news

Lixte Biotechnology Holdings, Inc. news in 2026

Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

July 6, 2026

LIXTE Joins Russell Microcap Index

June 26, 2026

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

June 18, 2026

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

June 12, 2026

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

June 3, 2026

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

June 1, 2026

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

May 14, 2026

LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

April 20, 2026

LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

April 13, 2026

Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships

April 10, 2026

LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year

April 2, 2026

LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

April 1, 2026

LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

March 31, 2026

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

March 30, 2026

Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership

March 27, 2026

Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming

March 25, 2026

LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

March 23, 2026

LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline

March 10, 2026

LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research

March 9, 2026

LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

February 18, 2026

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

February 18, 2026

LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

February 12, 2026

LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment

February 10, 2026

LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

February 9, 2026

Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective

February 5, 2026

LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

January 23, 2026

LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit

January 21, 2026

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

January 20, 2026

IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.

January 13, 2026

LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

January 8, 2026

Decks in 2026